# Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

Source: https://onco.cc/trials/nct06846268/  
OnCo record `nct06846268` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ADG126 and pembrolizumab in colorectal cancer, run by National University Hospital, Singapore, now recruiting.

## Summary

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer is a phase 2, interventional study registered as NCT06846268 by National University Hospital, Singapore, with a registry enrolment figure of 20 participants, started 2025-04-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: ADG126; Pembrolizumab. Conditions listed: Locally Advanced Colorectal Cancer. Primary outcome: Rate of Major Pathologic Response (MPR). Colorectal eligibility wording from the registry: "Histologically confirmed colorectal adenocarcinoma". Sites: Singapore. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06846268
- Phase: 2
- Setting: Phase II Trial of Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
- Sponsor: National University Hospital, Singapore
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06846268: https://clinicaltrials.gov/study/NCT06846268

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [ADG126](https://onco.cc/drugs/adg126/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06846268.json